Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have had their pancreatic cancer confirmed by a tissue sample (biopsy), specifically a type called pancreatic adenocarcinoma
• People whose cancer has spread to other parts of the body (metastatic) or has come back (recurrent) at the time of first diagnosis
• People who are generally well enough to carry out light activity and care for themselves (a doctor will assess this using a standard health scale)
• People whose cancer can be measured on a scan using standard medical criteria
• People whose heart test (ECG) shows no significant abnormalities, including no known irregular heart rhythms and a specific heart measurement (QTcF) within an acceptable range
• People whose recent blood test results (within the last 15 days before joining) show acceptable levels of red blood cells, white blood cells, infection-fighting cells (neutrophils), and platelets — without needing a recent transfusion to reach those levels
• People whose recent blood test results show acceptable liver function, kidney function, and blood clotting levels
• People with a condition called Gilbert's syndrome may still be eligible, as a slightly higher bilirubin level is allowed (confirm with trial site)
• People on blood-thinning medication whose clotting levels are within their target treatment range (confirm with trial site)
• People who test negative for pregnancy within 8 days before joining the trial (applies to those who could become pregnant)
• People who are willing to give written consent to participate
• People who are willing to provide blood and tissue samples for research purposes as required by the trial
• People who are willing to return to the enrolling site for follow-up visits during the active part of the study

Who may not be able to join:

• People who are pregnant or currently breastfeeding
• People who could become pregnant and are not willing to use effective contraception, as the study drug is known to carry risks of harm to a developing baby
• People who have not yet fully recovered from side effects of a minor surgical or medical procedure, or who have had a major surgical procedure (other than for diagnosis) within the 28 days before joining
• People with other serious ongoing illnesses or conditions that, in the treating doctor's judgement, could make participation unsafe or affect how the study results are assessed
• People with uncontrolled or active infections, or an unexplained fever above 38.5°C at the time of screening or first dose
• People who have had symptoms of heart failure, unstable chest pain (angina), or a coronary stent procedure or heart attack within the past year (timeframes vary by condition — confirm with trial site)
• People with an active irregular heart rhythm (arrhythmia)
• People who need continuous oxygen therapy due to breathing difficulties caused by their cancer or another condition
• People with certain lung conditions, including interstitial lung disease, pulmonary fibrosis, sarcoidosis, silicosis, hypersensitivity pneumonitis, or multiple allergies
• People with peripheral artery disease (a condition affecting blood flow in the limbs)
• People with psychiatric or personal circumstances that would make it difficult to follow the study requirements
• People with a current or past hepatitis B infection, or an active hepatitis C infection (people who have been fully and permanently cleared of hepatitis C may still be eligible — confirm with trial site)
• People living with HIV who have had a serious HIV-related infection in the past year, or whose CD4 immune cell count is below 350 — people with HIV may be eligible if they have been on stable HIV treatment for at least 4 weeks and meet other conditions (confirm with trial site)
• People whose pancreatic cancer type is neuroendocrine (carcinoid or islet cell) or acinar carcinoma, rather than adenocarcinoma
• People who have previously received chemotherapy for pancreatic cancer in the neoadjuvant or adjuvant setting, unless at least 12 months have passed since the last dose and there are no ongoing treatment-related side effects
• People currently taking part in another clinical trial using an investigational treatment for their cancer
• People who have had another active cancer in the past 5 years, with some exceptions — certain low-risk, fully treated, or non-progressive cancers may still be permitted (confirm with trial site)
• People with a history of heart attack in the 6 months before joining, or heart failure requiring ongoing treatment for life-threatening heart rhythm problems
• People who have previously received surgery, radiotherapy, chemotherapy, or investigational therapy specifically for pancreatic cancer that has spread (metastatic setting) — palliative radiotherapy and placement of a bile duct stent or tube are permitted
• People whose blood albumin (a protein) level is below 3 g/dL in the 15 days before joining
• People with a known history of cancer that has spread to the brain or spinal cord (CNS metastases)
• People with an active or suspected autoimmune disease, with some exceptions such as type 1 diabetes or an underactive thyroid requiring only hormone replacement
• People who have been taking steroid medications above a certain dose within the past 14 days, or other immune-suppressing medications within the past 30 days
• People who have previously been treated with certain types of immunotherapy drugs targeting PD-1, PD-L1, CTLA-4, or CCR8
• People who have received an organ or tissue transplant from another person
• People with a known allergy or sensitivity to the study drug (BMS-986340) or to any component of the combination treatments being used in the trial
• People who are not willing to follow the study's required procedures

Important: Always verify eligibility with the trial site directly before applying.